Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ascendis Pharma ADR (NQ: ASND ) 144.62 -2.74 (-1.86%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 516,852 Open 147.01 Bid (Size) 144.56 (36) Ask (Size) 144.89 (6) Prev. Close 147.36 Today's Range 142.98 - 148.31 52wk Range 85.28 - 161.00 Shares Outstanding 57,152,295 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Looking Into Ascendis Pharma's Recent Short Interest September 26, 2024 Via Benzinga BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish September 25, 2024 BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139... Via Benzinga Performance YTD +13.40% +13.40% 1 Month +4.20% +4.20% 3 Month +6.81% +6.81% 6 Month -4.33% -4.33% 1 Year +53.74% +53.74% More News Read More Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years September 24, 2024 Via Benzinga Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? September 22, 2024 Via Benzinga Topics Economy Exposures Interest Rates Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? September 22, 2024 Via Benzinga $100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today August 09, 2024 Via Benzinga $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today July 18, 2024 Via Benzinga Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term September 16, 2024 Via Benzinga Crude Oil Surges Over 1%; Instil Bio Shares Plunge September 16, 2024 Via Benzinga Exposures Fossil Fuels Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year September 16, 2024 Via Benzinga Exposures Product Safety Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug September 16, 2024 Via Investor's Business Daily Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday September 16, 2024 Via Benzinga Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today July 03, 2024 Via Benzinga Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years June 26, 2024 Via Benzinga If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today May 31, 2024 Via Benzinga Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In September 04, 2024 Via Benzinga Why Ascendis Pharma Stock Tumbled by 11% Today September 04, 2024 Via The Motley Fool Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout September 04, 2024 Via Investor's Business Daily Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut September 04, 2024 Via Benzinga Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session September 04, 2024 Via Benzinga Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement September 03, 2024 From Royalty Pharma plc Via GlobeNewswire Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday August 13, 2024 Via Benzinga Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues August 12, 2024 Via Benzinga Exposures Product Safety Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug August 12, 2024 Via Investor's Business Daily Exposures Product Safety Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday July 05, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
